Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

Launched by THE CLEVELAND CLINIC · Apr 7, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how effective an injectable treatment called fluocinolone acetonide is for patients with uveitis, a condition that causes inflammation in the eye. The goal is to observe patients who currently have active uveitis or have had it recently and to closely monitor their eye health over a 12-month period. Participants will undergo regular eye exams and imaging tests to measure inflammation and check how well they can see.

To be eligible for the trial, patients must have a diagnosis of uveitis and have been assessed by a specialist as having active or recently active inflammation. Unfortunately, some individuals won't qualify, such as those with certain eye conditions that make imaging difficult or who are under 18 years old, pregnant, or nursing. Throughout the study, participants will receive standard care and their vision will be tested at the beginning and end of the trial, along with follow-up exams and imaging to track any changes in their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist and requires an injectable fluocinolone acetonide implant to treat their inflammation.
• Exclusion Criteria:
• • - 1. Poor view in fundus in both eyes which precludes image acquisition in those with posterior uveitis 2. Those with any allergy to fluorescein 3. Corneal opacities which prevent image acquisition 4. Inability to sign consent 5. Poor candidates for injectable fluocinolone acetonide (advanced glaucoma without previous filtering surgery, chronic elevated IOP (\>25) on maximal topical anti-glaucoma drops and evidence of optic nerve progression.
• • 6. Children under the age of 18 and pregnant/nursing mothers.